Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of...
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- --...
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
LOUISVILLE, Ky., Sept. 24, 2025 /PRNewswire/ -- Cognision, a leader in high-performance neurophysiological biomarker solutions and services, has announced a...
Time-lapse video of a thymeleaf speedwell reveals the reproductive strategy select plants may adopt when pollinators are scarce MELVILLE, N.Y., Sept....
The Sontag Innovation Fund and the Yuvaan Tiwari Foundation join Two Bear Capital to support FYR's growing oncology portfolio and...
The academic health system was recognized for integrating innovative strategies and technologies to enhance safety and quality of care. TAMPA,...
Harnessing Neuroscience and Voice Mastery to Transform How Humans Communicate and Connect LOS ANGELES, Sept. 24, 2025 /PRNewswire/ -- NuCalm®,...
In this free webinar, learn how AI in scientific research is influencing translational practices and improving therapeutic development. Attendees will...
In this free webinar, learn why Latin America (LATAM) is becoming a strategic hotspot for ophthalmology clinical trials amid global...
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved...
Innovator of HD-EEG releases world’s most advanced EEG brain monitoring technology for neuroscience research EGI GES 500 Next-Generation HD-EEG Platform...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
The studies established the lead asset to be well tolerated in healthy volunteers at all doses with a good safety...
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner...
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®...
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with...
Bylvay® is the first once-daily ileal bile acid transport inhibitor to be approved as a treatment for pruritus associated with...